核酸作为继小分子、抗体之后的第三代药物类型，凭借高特异性、研发周期短、疗效亮眼、市场潜力大等优势，近年来持续升温，并迈入「爆发期」。 据不完全统计，2025 年已上市小核酸的销售额突破 70 亿美元（约 477.6 亿元人民币），Alnylam 的 ...

从“三强鼎立”，到“群雄逐鹿”。 2026年，中国小核酸药物正式迈入“资本元年”，赛道热度持续攀升。

As Chief Editor of one of the two journals in which Biopharma Dealmakers appears, I have a keen interest in the process of translating biomedical research into new drugs, including the partnerships ...

RNA therapies present significant opportunities in targeting a broad range of diseases through various innovative approaches, including antisense oligonucleotides, siRNAs, mRNA vaccines, and aptamers.